Andere Sprachen Eris Lifesciences Limited

Aktien

A2DU61

INE406M01024

ERIS

Markt geschlossen - NSE India S.E. Andere Börsenplätze 13:43:52 17.05.2024			% 5 Tage	% 1. Jan.
886.5 ^INR	+0.66%		+4.53%	-2.58%

03.04.	Eris Lifesciences schließt Übernahme des indischen Formulierungsgeschäfts von Biocon Biologics ab	MT
15.03.	Eris Lifesciences erwirbt das indische Formulierungsgeschäft von Biocon Biologics für 12,42 Milliarden INR	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	03.04.
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	15.03.
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	14.03.
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	14.03.
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	14.03.
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	16.02.
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	15.02.
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	13.02.
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13.02.
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	13.02.
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	08.02.
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	10.11.
Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations, India Business Units	09.11.
Indian shares set to open higher tracking Asian peers	09.11.
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	08.11.
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	08.11.
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	08.11.
Eris Lifesciences Limited Enters into Term Loan Agreement to Avail the Rupee Term Loan Facility from HDFC Bank Limited	29.09.23
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07.08.23
Eris Lifesciences Gains Dermatology Trademarks Acquired from Glenmark via Deal with Unit Eris Oaknet	04.07.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Eris Lifesciences Limited

Aktien

A2DU61

INE406M01024

ERIS

Andere Sprachen

Filter